Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
TA

NYSE · TAK

Takeda Pharmaceutical Company Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$20.91

Up+$0.90 (+4.50%)

Updated Oct 31, 2026, 4:29 PM

SID Score

5.8/10

Composite research score

Smart Money

56/100

Neutral

Market cap
45.42B
P/E ratio
50.83
Dividend yield
3.16%
52-week range
$13.50 – $20.55
Volume
4.62M
Avg. volume
2.78M

Price performance · TAK

TAK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

TAK closed at $20.91 after 21 trading sessions, up 17.08% for the selected period.

Last close
$20.91
Period change
+17.08%
Period low
$17.81
Period high
$20.91
Daily close
View OHLC price history
TAK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$21.00$21.22$20.79$20.914.62M
Oct 29, 2026$20.00$20.325$19.50$20.014.81M
Oct 28, 2026$19.78$20.235$19.78$20.153.12M
Oct 27, 2026$20.19$20.37$20.19$20.272.15M
Oct 26, 2026$20.40$20.5512$20.355$20.432.37M
Oct 23, 2026$20.28$20.39$20.17$20.242.1M
Oct 22, 2026$20.18$20.39$20.08$20.363.46M
Oct 21, 2026$19.90$20.0299$19.90$19.931.67M
Oct 20, 2026$19.90$20.13$19.84$20.082.91M
Oct 19, 2026$19.55$19.80$19.55$19.612.88M
Oct 16, 2026$19.67$19.705$19.5606$19.672.83M
Oct 15, 2026$19.58$19.89$19.45$19.454.39M
Oct 14, 2026$18.63$19.04$18.57$19.014.68M
Oct 13, 2026$18.73$18.82$18.52$18.522.93M
Oct 12, 2026$18.79$18.79$18.655$18.681.91M
Oct 9, 2026$18.37$18.755$18.37$18.732.04M
Oct 8, 2026$18.39$18.52$18.215$18.523.51M
Oct 7, 2026$18.14$18.4551$18.14$18.372.56M
Oct 6, 2026$17.97$18.179$17.955$18.103.1M
Oct 5, 2026$17.78$17.91$17.75$17.813.4M
Oct 2, 2026$17.85$17.89$17.78$17.862.13M

Latest TAK news

The latest Smart Investors Daily articles mentioning TAK.

Stock researchCompany · Overview

TAK research

Overview

Company profile and research snapshot.

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TAK recent ratings
DateFirmRatingTarget
Mar 11, 2020JP MorganOverweight—
Nov 1, 2019Cowen & Co.Market Perform—
Sep 24, 2019JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

OSAKA, Japan & CAMBRIDGE, Mass., October 23, 2026--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncolo

Benzinga · Oct 23, 2026

Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements

Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints

Yahoo · Oct 20, 2026

Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)

Takeda Pharmaceutical reported new Phase 4 VERDICT data showing that intravenous ENTYVIO achieved corticosteroid free disease clearance in moderate to severe ulcerative colitis and was associated with a lower risk of UC related complications compared with targeting symptomatic remission alone. The trial used a treat to target design with increasingly strict remission goals and found that aiming for deep disease clearance extended the time to first UC complication without introducing new...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By